LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・Alkermes PLC

Alkermes PLC

Suletud

SektorTervishoid

29.5 0.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.84

Max

29.57

Põhinäitajad
By Trading Economics
Sissetulek	-4.3M 83M
Müük	3.5M 394M
P/E Sektori keskmine	14.378 80.03
Aktsiakasum	0.651
Kasumimarginaal	20.995
Töötajad	1,800
EBITDA	-3.8M 109M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+51.88% upside

Turustatistika
By TradingEconomics
Turukapital	-134M 4.8B
Eelmine avamishind	28.85
Eelmine sulgemishind	29.5

Uudiste sentiment

By Acuity

50%

184 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

27.95 / 30.91 Toetus ja vastupanu

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 12:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pharma Sector Becoming Bidding Battlefield -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

51.88% tõus

12 kuu keskmine prognoos

Keskmine 44.5 USD 51.88%

Kõrge 58 USD

Madal 34 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Alkermes PLC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

27.95 / 30.91Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bearish.

All events are bullish.

Sentiment

By Acuity

184 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.